Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroleptic malignant syndrome: an overview

J S Persing1

  • 1USD School of Medicine, Department of Student Affairs, Sioux Falls.

South Dakota Journal of Medicine
|February 1, 1994
PubMed
Summary

Neuroleptic Malignant Syndrome (NMS) is a rare but serious reaction to dopamine antagonists. Early diagnosis and treatment have significantly reduced NMS mortality rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypochondriasis: the patient's perspective.

International journal of psychiatry in medicine·2001
Same author

The endogenous inhibitor of protein kinase-C in the rat ovary is a protein phosphatase.

Endocrinology·1993
See all related articles

Area of Science:

  • Neurology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Neuroleptic Malignant Syndrome (NMS) is a life-threatening condition associated with dopamine antagonist medications.
  • Key features include hyperthermia, muscle rigidity, altered mental status, and autonomic instability.

Purpose of the Study:

  • To review the incidence, mortality, and treatment of Neuroleptic Malignant Syndrome.
  • To discuss the potential for reinstitution of dopamine antagonist therapy after an NMS episode.

Main Methods:

  • Literature review of NMS cases and treatment outcomes.
  • Analysis of incidence rates and mortality trends over time.
  • Summary of current and experimental therapeutic strategies.

Main Results:

  • NMS incidence ranges from 0.02% to 3.23% in patients on dopamine antagonists.
  • Mortality has decreased from 25% pre-1984 to 11.6% post-1984, likely due to increased awareness and improved treatments.
  • Treatment involves drug withdrawal, fever control, dopamine agonists, and dantrolene; ECT is an option for refractory cases.

Conclusions:

  • Neuroleptic Malignant Syndrome, while rare, carries significant mortality but is increasingly manageable.
  • Early recognition and intervention are crucial for improving patient outcomes.
  • Recurrence risk is approximately 30% if specific protocols are followed when reinstituting therapy.

Related Experiment Videos